Treatment outcomes of advanced digestive well-differentiated grade 3 NETs.

Date publication

juin 2021

Journal

Endocrine-related cancer

Auteurs

Membres identifiés du Cancéropôle Est :
Pr CADIOT Guillaume

Tous les auteurs :
de Mestier L, Lamarca A, Hernando J, Zandee W, Alonso-Gordoa T, Perrier M, Walenkamp AME, Chakrabarty B, Landolfi S, Van Velthuysen MF, Kats-Ugurlu G, Carminoa A, Ronot M, Manoharan P, Garcia-Alvarez A, Brabander T, García Gómez-Muriel MI, Cadiot G, Couvelard A, Capdevilla J, Pavel ME, Cros J

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/34061764

Résumé

There is no standardized treatment for grade 3 neuroendocrine tumors (G3 NETs). We aimed to describe the treatments received in patients with advanced G3 NETs and compare their efficacy. Patients with advanced digestive G3 NETs treated between 2010 and 2018 in seven expert centers were retrospectively studied. Pathological samples were centrally reviewed, and radiological data were locally reviewed. We analyzed RECIST-defined objective response (OR), tumor growth rate (TGR) and progression-free survival (PFS) obtained with first- (L1) or second-line (L2) treatments. We included 74 patients with advanced G3 NETs, mostly from duodenal or pancreatic origin (71.6%), with median Ki-67 of 30%. The 126 treatments (L1=74; L2=52) included alkylating-based (n=32), etoposide-platinum (n=22) or adenocarcinoma-like chemotherapy (n=20), somatostatin analogs (n=21), targeted therapies (n=22) and liver-directed therapies (n=7). Alkylating-based chemotherapy achieved the highest OR rate (37.9%) compared to other treatments (multivariable OR 4.22, 95% CI [1.5-12.2]; p=0.008). Adenocarcinoma-like and alkylating-based chemotherapies showed the highest reductions in 3-month TGR (p<0.001 and p=0.008, respectively). The longest median PFS were obtained with adenocarcinoma-like chemotherapy (16.5 months [9.0-24.0]) and targeted therapies (12.0 months [8.2-15.8]), while the shortest PFS were observed with somatostatin analogues (6.2 months [3.8-8.5]) and etoposide-platinum chemotherapy (7.2 months [5.2-9.1]). Etoposide-platinum CT achieved shorter PFS than adenocarcinoma-like (multivariable HR 3.69 [1.61-8.44], p=0.002) and alkylating-based chemotherapies (multivariable HR 1.95 [1.01-3.78], p=0.049). Overall, adenocarcinoma-like and alkylating-based chemotherapies may be the most effective treatments for patients with advanced G3 NETs regarding OR and PFS. Etoposide-platinum chemotherapy has poor efficacy in this setting.

Référence

Endocr Relat Cancer. 2021 Jun 1;: